<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35889517</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>31</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1420-3049</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>14</Issue><PubDate><Year>2022</Year><Month>Jul</Month><Day>21</Day></PubDate></JournalIssue><Title>Molecules (Basel, Switzerland)</Title><ISOAbbreviation>Molecules</ISOAbbreviation></Journal><ArticleTitle>Inosine in Neurodegenerative Diseases: From the Bench to the Bedside.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">4644</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/molecules27144644</ELocationID><Abstract><AbstractText>Neurodegenerative diseases, such as Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS), currently represent major unmet medical needs. Therefore, novel therapeutic strategies are needed in order to improve patients' quality of life and prognosis. Since oxidative stress can be strongly involved in neurodegenerative diseases, the potential use of inosine, known for its antioxidant properties, in this context deserves particular attention. The protective action of inosine treatment could be mediated by its metabolite urate. Here, we review the current preclinical and clinical studies investigating the use of inosine in AD, PD, ALS, and MS. The most important properties of inosine seem to be its antioxidant action and its ability to raise urate levels and to increase energetic resources by improving ATP availability. Inosine appears to be generally safe and well tolerated; however, the possible formation of kidney stones should be monitored, and data on its effectiveness should be further explored since, so far, they have been controversial. Overall, inosine could be a promising potential strategy in the management of neurodegenerative diseases, and additional studies are needed in order to further investigate its safety and efficacy and its use as a complementary therapy along with other approved drugs.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Basile</LastName><ForeName>Maria Sofia</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>IRCCS Centro Neurolesi "Bonino-Pulejo", Via Provinciale Palermo, Contrada Casazza, 98124 Messina, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bramanti</LastName><ForeName>Placido</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>IRCCS Centro Neurolesi "Bonino-Pulejo", Via Provinciale Palermo, Contrada Casazza, 98124 Messina, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mazzon</LastName><ForeName>Emanuela</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>IRCCS Centro Neurolesi "Bonino-Pulejo", Via Provinciale Palermo, Contrada Casazza, 98124 Messina, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Current Research Funds 2022</GrantID><Agency>Ministry of Health, Italy</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Molecules</MedlineTA><NlmUniqueID>100964009</NlmUniqueID><ISSNLinking>1420-3049</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance></Chemical><Chemical><RegistryNumber>268B43MJ25</RegistryNumber><NameOfSubstance UI="D014527">Uric Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>5A614L51CT</RegistryNumber><NameOfSubstance UI="D007288">Inosine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000975" MajorTopicYN="N">Antioxidants</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007288" MajorTopicYN="N">Inosine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009103" MajorTopicYN="Y">Multiple Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014527" MajorTopicYN="N">Uric Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2032;s disease</Keyword><Keyword MajorTopicYN="N">Parkinson&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">inosine</Keyword><Keyword MajorTopicYN="N">multiple sclerosis</Keyword><Keyword MajorTopicYN="N">neurodegenerative diseases</Keyword><Keyword MajorTopicYN="N">urate</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>27</Day><Hour>1</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35889517</ArticleId><ArticleId IdType="pmc">PMC9316764</ArticleId><ArticleId IdType="doi">10.3390/molecules27144644</ArticleId><ArticleId IdType="pii">molecules27144644</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Crotty G.F., Ascherio A., Schwarzschild M.A. Targeting urate to reduce oxidative stress in Parkinson disease. Exp. Neurol. 2017;298:210. doi: 10.1016/j.expneurol.2017.06.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2017.06.017</ArticleId><ArticleId IdType="pmc">PMC5693633</ArticleId><ArticleId IdType="pubmed">28622913</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Shamarka M.E.A., Kozman M.R., Messiha B.A.S. The protective effect of inosine against rotenone-induced Parkinson&#x2019;s disease in mice; role of oxido-nitrosative stress, ERK phosphorylation, and A2AR expression. Naunyn. Schmiedebergs. Arch. Pharmacol. 2020;393:1041&#x2013;1053. doi: 10.1007/s00210-019-01804-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00210-019-01804-1</ArticleId><ArticleId IdType="pubmed">31915844</ArticleId></ArticleIdList></Reference><Reference><Citation>Cipriani S., Bakshi R., Schwarzschild M.A. Protection by inosine in a cellular model of Parkinson&#x2019;s disease. Neuroscience. 2014;274:242. doi: 10.1016/j.neuroscience.2014.05.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2014.05.038</ArticleId><ArticleId IdType="pmc">PMC4120965</ArticleId><ArticleId IdType="pubmed">24880154</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott G.S., Spitsin S.V., Kean R.B., Mikheeva T., Koprowski H., Hooper D.C. Therapeutic intervention in experimental allergic encephalomyelitis by administration of uric acid precursors. Proc. Natl. Acad. Sci. USA. 2002;99:16303&#x2013;16308. doi: 10.1073/pnas.212645999.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.212645999</ArticleId><ArticleId IdType="pmc">PMC138606</ArticleId><ArticleId IdType="pubmed">12451183</ArticleId></ArticleIdList></Reference><Reference><Citation>Nascimento F.P., Macedo-J&#xfa;nior S.J., Lapa-Costa F.R., Cezar-Dos-Santos F., Santos A.R.S. Inosine as a Tool to Understand and Treat Central Nervous System Disorders: A Neglected Actor? Front. Neurosci. 2021;15:1014. doi: 10.3389/fnins.2021.703783.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2021.703783</ArticleId><ArticleId IdType="pmc">PMC8421806</ArticleId><ArticleId IdType="pubmed">34504414</ArticleId></ArticleIdList></Reference><Reference><Citation>Markowitz C.E., Spitsin S., Zimmerman V., Jacobs D., Udupa J.K., Hooper D.C., Koprowski H., TE W. The Treatment of Multiple Sclerosis with Inosine. J. Altern. Complement. Med. 2009;15:619. doi: 10.1089/acm.2008.0513.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/acm.2008.0513</ArticleId><ArticleId IdType="pmc">PMC3189001</ArticleId><ArticleId IdType="pubmed">19425822</ArticleId></ArticleIdList></Reference><Reference><Citation>Oertel W., Schulz J.B. Current and experimental treatments of Parkinson disease: A guide for neuroscientists. J. Neurochem. 2016;139:325&#x2013;337. doi: 10.1111/jnc.13750.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13750</ArticleId><ArticleId IdType="pubmed">27577098</ArticleId></ArticleIdList></Reference><Reference><Citation>Sliva J., Pantzartzi C.N., Votava M. Inosine Pranobex: A Key Player in the Game Against a Wide Range of Viral Infections and Non-Infectious Diseases. Adv. Ther. 2019;36:1878. doi: 10.1007/s12325-019-00995-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12325-019-00995-6</ArticleId><ArticleId IdType="pmc">PMC6822865</ArticleId><ArticleId IdType="pubmed">31168764</ArticleId></ArticleIdList></Reference><Reference><Citation>ALSUntangled Group ALSUntangled No. 37: Inosine. Amyotroph. Lateral Scler. Front. Degener. 2016;18:309&#x2013;312. doi: 10.1080/21678421.2016.1223270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1223270</ArticleId><ArticleId IdType="pubmed">27575981</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarzschild M.A., Ascherio A., Beal M.F., Cudkowicz M.E., Curhan G.C., Hare J.M., Hooper D.C., Kieburtz K.D., Macklin E.A., Oakes D., et al. Inosine to increase serum and CSF urate in Parkinson disease: A randomized, placebo-controlled trial. JAMA Neurol. 2014;71:141. doi: 10.1001/jamaneurol.2013.5528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.5528</ArticleId><ArticleId IdType="pmc">PMC3940333</ArticleId><ArticleId IdType="pubmed">24366103</ArticleId></ArticleIdList></Reference><Reference><Citation>Guttuso T., Andrzejewski K.L., Lichter D.G., Andersen J.K. Targeting kinases in Parkinson&#x2019;s disease: A mechanism shared by LRRK2, neurotrophins, exenatide, urate, nilotinib and lithium. J. Neurol. Sci. 2019;402:121&#x2013;130. doi: 10.1016/j.jns.2019.05.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2019.05.016</ArticleId><ArticleId IdType="pubmed">31129265</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S., Nicholson K., Chan J., Shui A., Schoenfeld D., Sherman A., Berry J., Cudkowicz M., Atassi N. For the Pooled Resource Open-Access ALS Clinical Trials Consortium. Urate levels predict survival in amyotrophic lateral sclerosis: Analysis of the expanded Pooled Resource Open-Access ALS clinical trials database. Muscle Nerve. 2018;57:430&#x2013;434. doi: 10.1002/mus.25950.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.25950</ArticleId><ArticleId IdType="pmc">PMC5812805</ArticleId><ArticleId IdType="pubmed">28857199</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X., Burdett T.C., Desjardins C.A., Logan R., Cipriani S., Xu Y., Schwarzschild M.A. Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration. Proc. Natl. Acad. Sci. USA. 2013;110:300&#x2013;305. doi: 10.1073/pnas.1217296110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1217296110</ArticleId><ArticleId IdType="pmc">PMC3538212</ArticleId><ArticleId IdType="pubmed">23248282</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarty M.F., Barroso-Aranda J., Contreras F. High-dose folate and dietary purines promote scavenging of peroxynitrite-derived radicals&#x2014;Clinical potential in inflammatory disorders. Med. Hypotheses. 2009;73:824&#x2013;834. doi: 10.1016/j.mehy.2008.09.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2008.09.058</ArticleId><ArticleId IdType="pubmed">19409716</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe H., Hattori T., Kume A., Misu K., Ito T., Koike Y., Johnson T.A., Kamitsuji S., Kamatani N., Sobue G. Improved Parkinsons disease motor score in a single-arm open-label trial of febuxostat and inosine. Medicine. 2020;99:e21576. doi: 10.1097/MD.0000000000021576.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000021576</ArticleId><ArticleId IdType="pmc">PMC7458241</ArticleId><ArticleId IdType="pubmed">32871874</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S., Schwarzschild M.A. Urate as a Marker of Risk and Progression of Neurodegenerative Disease. Neurotherapeutics. 2017;14:148. doi: 10.1007/s13311-016-0497-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-016-0497-4</ArticleId><ArticleId IdType="pmc">PMC5233635</ArticleId><ArticleId IdType="pubmed">27995438</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarty M.F., Lerner A. Nutraceuticals Targeting Generation and Oxidant Activity of Peroxynitrite May Aid Prevention and Control of Parkinson&#x2019;s Disease. Int. J. Mol. Sci. 2020;21:3624. doi: 10.3390/ijms21103624.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21103624</ArticleId><ArticleId IdType="pmc">PMC7279222</ArticleId><ArticleId IdType="pubmed">32455532</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a D.M., Midaglia L., Vilela J.M., S&#xe1;nchez M.M., Gonz&#xe1;lez F.J.L., G&#xf3;mez M.A., Bola&#xf1;o D.D., Casta&#xf1;&#xf3;n A.I., Alonso M.A., L&#xf3;pez J.R. Associated Inosine to interferon: Results of a clinical trial in multiple sclerosis. Acta Neurol. Scand. 2015;131:405&#x2013;410. doi: 10.1111/ane.12333.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ane.12333</ArticleId><ArticleId IdType="pubmed">25313094</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerou M., Hall B., Woof R., Allsop J., Kolb S.J., Meyer K., Shaw P.J., Allen S.P. Amyotrophic lateral sclerosis alters the metabolic aging profile in patient derived fibroblasts. Neurobiol. Aging. 2021;105:64. doi: 10.1016/j.neurobiolaging.2021.04.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2021.04.013</ArticleId><ArticleId IdType="pmc">PMC8346650</ArticleId><ArticleId IdType="pubmed">34044197</ArticleId></ArticleIdList></Reference><Reference><Citation>Petralia M.C., Battaglia G., Bruno V., Pennisi M., Mangano K., Lombardo S.D., Fagone P., Cavalli E., Saraceno A., Nicoletti F., et al. The Role of Macrophage Migration Inhibitory Factor in Alzheimer&#x2032;s Disease: Conventionally Pathogenetic or Unconventionally Protective? Molecules. 2020;25:291. doi: 10.3390/molecules25020291.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules25020291</ArticleId><ArticleId IdType="pmc">PMC7024279</ArticleId><ArticleId IdType="pubmed">31936865</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardo-Moreno T., Gonz&#xe1;lez-Acedo A., Rivas-Dom&#xed;nguez A., Garc&#xed;a-Morales V., Garc&#xed;a-Cozar F.J., Ramos-Rodr&#xed;guez J.J., Melguizo-Rodr&#xed;guez L. Therapeutic Approach to Alzheimer&#x2019;s Disease: Current Treatments and New Perspectives. Pharmaceutics. 2022;14:1117. doi: 10.3390/pharmaceutics14061117.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics14061117</ArticleId><ArticleId IdType="pmc">PMC9228613</ArticleId><ArticleId IdType="pubmed">35745693</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman D.S., Amieva H., Petersen R.C., Ch&#xe9;telat G., Holtzman D.M., Hyman B.T., Nixon R.A., Jones D.T. Alzheimer disease. Nat. Rev. Dis. Prim. 2021;7:33. doi: 10.1038/s41572-021-00269-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41572-021-00269-y</ArticleId><ArticleId IdType="pmc">PMC8574196</ArticleId><ArticleId IdType="pubmed">33986301</ArticleId></ArticleIdList></Reference><Reference><Citation>Weller J., Budson A. Current understanding of Alzheimer&#x2019;s disease diagnosis and treatment. F1000Research. 2018;7:1161. doi: 10.12688/f1000research.14506.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.14506.1</ArticleId><ArticleId IdType="pmc">PMC6073093</ArticleId><ArticleId IdType="pubmed">30135715</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S., Kong X., Chen Z., Wang G., Zhang J., Wang J. Role of Natural Compounds and Target Enzymes in the Treatment of Alzheimer&#x2019;s Disease. Molecules. 2022;27:4175. doi: 10.3390/molecules27134175.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules27134175</ArticleId><ArticleId IdType="pmc">PMC9268689</ArticleId><ArticleId IdType="pubmed">35807418</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z., Zhong C. Oxidative stress in Alzheimer&#x2019;s disease. Neurosci. Bull. 2014;30:271&#x2013;281. doi: 10.1007/s12264-013-1423-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12264-013-1423-y</ArticleId><ArticleId IdType="pmc">PMC5562667</ArticleId><ArticleId IdType="pubmed">24664866</ArticleId></ArticleIdList></Reference><Reference><Citation>McFarland N.R., Burdett T., Desjardins C.A., Frosch M.P., Schwarzschild M.A. Postmortem brain levels of urate and precursors in Parkinson&#x2019;s disease and related disorders. Neurodegener. Dis. 2013;12:189&#x2013;198. doi: 10.1159/000346370.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000346370</ArticleId><ArticleId IdType="pmc">PMC3809155</ArticleId><ArticleId IdType="pubmed">23467193</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang N., Yan X., Zhou W., Zhang Q., Chen H., Zhang Y., Zhang X. NMR-based metabonomic investigations into the metabolic profile of the senescence-accelerated mouse. J. Proteome Res. 2008;7:3678&#x2013;3686. doi: 10.1021/pr800439b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/pr800439b</ArticleId><ArticleId IdType="pubmed">18656976</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez-Dom&#xed;nguez R., Garc&#xed;a-Barrera T., Vitorica J., G&#xf3;mez-Ariza J.L. Application of metabolomics based on direct mass spectrometry analysis for the elucidation of altered metabolic pathways in serum from the APP/PS1 transgenic model of Alzheimer&#x2019;s disease. J. Pharm. Biomed. Anal. 2015;107:378&#x2013;385. doi: 10.1016/j.jpba.2015.01.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpba.2015.01.025</ArticleId><ArticleId IdType="pubmed">25656489</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen J.E., Maltesen R.G., Havelund J.F., F&#xe6;rgeman N.J., Gotfredsen C.H., Vesterg&#xe5;rd K., Kristensen S.R., Pedersen S. Characterising Alzheimer&#x2019;s disease through integrative NMR- and LC-MS-based metabolomics. Metab. Open. 2021;12:100125. doi: 10.1016/j.metop.2021.100125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metop.2021.100125</ArticleId><ArticleId IdType="pmc">PMC8479251</ArticleId><ArticleId IdType="pubmed">34622190</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso-Andr&#xe9;s P., Albasanz J.L., Ferrer I., Mart&#xed;n M. Purine-related metabolites and their converting enzymes are altered in frontal, parietal and temporal cortex at early stages of Alzheimer&#x2019;s disease pathology. Brain Pathol. 2018;28:933&#x2013;946. doi: 10.1111/bpa.12592.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12592</ArticleId><ArticleId IdType="pmc">PMC8028663</ArticleId><ArticleId IdType="pubmed">29363833</ArticleId></ArticleIdList></Reference><Reference><Citation>Waugh W.H. Inhibition of iron-catalyzed oxidations by attainable uric acid and ascorbic acid levels: Therapeutic implications for Alzheimer&#x2019;s disease and late cognitive impairment. Gerontology. 2008;54:238&#x2013;243. doi: 10.1159/000122618.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000122618</ArticleId><ArticleId IdType="pubmed">18367828</ArticleId></ArticleIdList></Reference><Reference><Citation>Teixeira F.C., Gutierres J.M., Soares M.S.P., da Siveira de Mattos B., Spohr L., do Couto C.A.T., Bona N.P., Assmann C.E., Morsch V.M., da Cruz I.B.M., et al. Inosine protects against impairment of memory induced by experimental model of Alzheimer disease: A nucleoside with multitarget brain actions. Psychopharmacology. 2020;237:811&#x2013;823. doi: 10.1007/s00213-019-05419-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00213-019-05419-5</ArticleId><ArticleId IdType="pubmed">31834453</ArticleId></ArticleIdList></Reference><Reference><Citation>Teixeira F.C., Soares M.S.P., Bl&#xf6;dorn E.B., Domingues W.B., Reichert K.P., Zago A.M., Carvalho F.B., Gutierres J.M., Gon&#xe7;ales R.A., da Cruz Fernandes M., et al. Investigating the Effect of Inosine on Brain Purinergic Receptors and Neurotrophic and Neuroinflammatory Parameters in an Experimental Model of Alzheimer&#x2019;s Disease. Mol. Neurobiol. 2022;59:841&#x2013;855. doi: 10.1007/s12035-021-02627-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-021-02627-z</ArticleId><ArticleId IdType="pubmed">34792730</ArticleId></ArticleIdList></Reference><Reference><Citation>Teixeira F.C., de Mattos B.D.S., de Mello J.E., Cardoso J., Spohr L., Luduvico K.P., Soares M.S.P., Carvalho F.B., Gutierres J.M., de Oliveira Campello Felix A., et al. Protective Effects of Inosine on Memory Consolidation in a Rat Model of Scopolamine-Induced Cognitive Impairment: Involvement of Cholinergic Signaling, Redox Status, and Ion Pump Activities. Neurochem. Res. 2022;47:446&#x2013;460. doi: 10.1007/s11064-021-03460-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-021-03460-5</ArticleId><ArticleId IdType="pubmed">34623562</ArticleId></ArticleIdList></Reference><Reference><Citation>Tysnes O.B., Storstein A. Epidemiology of Parkinson&#x2019;s disease. J. Neural Transm. 2017;124:901&#x2013;905. doi: 10.1007/s00702-017-1686-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-017-1686-y</ArticleId><ArticleId IdType="pubmed">28150045</ArticleId></ArticleIdList></Reference><Reference><Citation>Basile M.S., Battaglia G., Bruno V., Mangano K., Fagone P., Petralia M.C., Nicoletti F., Cavalli E. The Dichotomic Role of Macrophage Migration Inhibitory Factor in Neurodegeneration. Int. J. Mol. Sci. 2020;21:3023. doi: 10.3390/ijms21083023.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21083023</ArticleId><ArticleId IdType="pmc">PMC7216212</ArticleId><ArticleId IdType="pubmed">32344747</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein C., Westenberger A. Genetics of Parkinson&#x2019;s disease. Cold Spring Harb. Perspect. Med. 2012;2:a008888. doi: 10.1101/cshperspect.a008888.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a008888</ArticleId><ArticleId IdType="pmc">PMC3253033</ArticleId><ArticleId IdType="pubmed">22315721</ArticleId></ArticleIdList></Reference><Reference><Citation>Balestrino R., Schapira A.H.V. Parkinson disease. Eur. J. Neurol. 2020;27:27&#x2013;42. doi: 10.1111/ene.14108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14108</ArticleId><ArticleId IdType="pubmed">31631455</ArticleId></ArticleIdList></Reference><Reference><Citation>Alborghetti M., Nicoletti F. Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson&#x2019;s Disease: From Bench to Bedside. Curr. Neuropharmacol. 2019;17:861&#x2013;873. doi: 10.2174/1570159X16666180830100754.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1570159X16666180830100754</ArticleId><ArticleId IdType="pmc">PMC7052841</ArticleId><ArticleId IdType="pubmed">30160213</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharyya S., Bakshi R., Logan R., Ascherio A., Macklin E.A., Schwarzschild M.A. Oral Inosine Persistently Elevates Plasma antioxidant capacity in Parkinson&#x2019;s disease. Mov. Disord. 2016;31:417&#x2013;421. doi: 10.1002/mds.26483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.26483</ArticleId><ArticleId IdType="pubmed">26805433</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang N., Shu H.-Y., Huang T., Zhang Q.-L., Li D., Zhang G.-Q., Peng X.-Y., Liu C.-F., Luo W.-F., Hu L.-F. Nrf2 Signaling Contributes to the Neuroprotective Effects of Urate against 6-OHDA Toxicity. PLoS ONE. 2014;9:e100286. doi: 10.1371/journal.pone.0100286.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0100286</ArticleId><ArticleId IdType="pmc">PMC4069024</ArticleId><ArticleId IdType="pubmed">24959672</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong L., Zhang Q.-L., Zhang N., Hua W.-Y., Huang Y.-X., Di P.W., Huang T., Xu X., Liu C.-F., Hu L.-F., et al. Neuroprotection by urate on 6-OHDA-lesioned rat model of Parkinson&#x2019;s disease: Linking to Akt/GSK3&#x3b2; signaling pathway. J. Neurochem. 2012;123:876&#x2013;885. doi: 10.1111/jnc.12038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.12038</ArticleId><ArticleId IdType="pubmed">23094836</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakashima A., Yamauchi A., Matsumoto J., Dohgu S., Takata F., Koga M., Fukae J., Tsuboi Y., Kataoka Y. Feeding-produced subchronic high plasma levels of uric acid improve behavioral dysfunction in 6-hydroxydopamine-induced mouse model of Parkinson&#x2019;s disease. Behav. Pharmacol. 2019;30:89&#x2013;94. doi: 10.1097/FBP.0000000000000413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/FBP.0000000000000413</ArticleId><ArticleId IdType="pubmed">29847340</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisskopf M.G., O&#x2019;Reilly E., Chen H., Schwarzschild M.A., Ascherio A. Plasma urate and risk of Parkinson&#x2019;s disease. Am. J. Epidemiol. 2007;166:561. doi: 10.1093/aje/kwm127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwm127</ArticleId><ArticleId IdType="pmc">PMC2391073</ArticleId><ArticleId IdType="pubmed">17584757</ArticleId></ArticleIdList></Reference><Reference><Citation>De Lau L.M.L., Koudstaal P.J., Hofman A., Breteler M.M. Serum uric acid levels and the risk of Parkinson disease. Ann. Neurol. 2005;58:797&#x2013;800. doi: 10.1002/ana.20663.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.20663</ArticleId><ArticleId IdType="pubmed">16240356</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarzschild M.A., Schwid S.R., Marek K., Watts A., Lang A.E., Oakes D., Shoulson I., Ascherio A., Parkinson Study Group PRECEPT Investigators. Hyson C., et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch. Neurol. 2008;65:716&#x2013;723. doi: 10.1001/archneur.2008.65.6.nct70003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.2008.65.6.nct70003</ArticleId><ArticleId IdType="pmc">PMC2574855</ArticleId><ArticleId IdType="pubmed">18413464</ArticleId></ArticleIdList></Reference><Reference><Citation>Ascherio A., LeWitt P.A., Xu K., Eberly S., Watts A., Matson W.R., Marras C., Kieburtz K., Rudolph A., Bogdanov M.B., et al. Urate predicts rate of clinical decline in Parkinson disease. Arch. Neurol. 2009;66:1460. doi: 10.1001/archneurol.2009.247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2009.247</ArticleId><ArticleId IdType="pmc">PMC2795011</ArticleId><ArticleId IdType="pubmed">19822770</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X., Umeh C.C., Tainsh R.E., Feng D.D., Maguire M., Zuo F., Rahimian M., Logan R., Wang X., Ascherio A., et al. Dissociation between urate and blood pressure in mice and in people with early Parkinson&#x2019;s disease. EBioMedicine. 2018;37:259&#x2013;268. doi: 10.1016/j.ebiom.2018.10.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2018.10.039</ArticleId><ArticleId IdType="pmc">PMC6284456</ArticleId><ArticleId IdType="pubmed">30415890</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarzschild M.A., Macklin E.A., Bakshi R., Battacharyya S., Logan R., Espay A.J., Hung A.Y., Bwala G., Goetz C.G., Russell D.S., et al. Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial. Neurology. 2019;93:E1328&#x2013;E1338. doi: 10.1212/WNL.0000000000008194.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000008194</ArticleId><ArticleId IdType="pmc">PMC6814412</ArticleId><ArticleId IdType="pubmed">31484712</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwaki H., Ando R., Miyaue N., Tada S., Tsujii T., Yabe H., Nishikawa N., Nagai M., Nomoto M. One year safety and efficacy of inosine to increase the serum urate level for patients with Parkinson&#x2019;s disease in Japan. J. Neurol. Sci. 2017;383:75&#x2013;78. doi: 10.1016/j.jns.2017.10.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2017.10.030</ArticleId><ArticleId IdType="pubmed">29246629</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkinson Study Group SURE-PD3 Investigators. Schwarzschild M.A., Ascherio A., Casaceli C., Curhan G.C., Fitzgerald R., Kamp C., Lungu C., Macklin E.A., Marek K., et al. Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial. JAMA. 2021;326:926&#x2013;939. doi: 10.1001/JAMA.2021.10207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/JAMA.2021.10207</ArticleId><ArticleId IdType="pmc">PMC8441591</ArticleId><ArticleId IdType="pubmed">34519802</ArticleId></ArticleIdList></Reference><Reference><Citation>Talbott E.O., Malek A.M., Lacomis D. Handbook of Clinical Neurology. Volume 138. Elsevier; Amsterdam, The Netherlands: 2016. The epidemiology of amyotrophic lateral sclerosis; pp. 225&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pubmed">27637961</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es M.A., Hardiman O., Chio A., Al-Chalabi A., Pasterkamp R.J., Veldink J.H., van den Berg L.H. Amyotrophic lateral sclerosis. Lancet. 2017;390:2084&#x2013;2098. doi: 10.1016/S0140-6736(17)31287-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31287-4</ArticleId><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O., Al-Chalabi A., Chio A., Corr E.M., Logroscino G., Robberecht W., Shaw P.J., Simmons Z., van den Berg L.H. Amyotrophic lateral sclerosis. Nat. Rev. Dis. Prim. 2017;3:17071. doi: 10.1038/nrdp.2017.71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.71</ArticleId><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulisz D. Amyotrophic lateral sclerosis: Disease state overview. Am. J. Manag. Care. 2018;24:S320&#x2013;S326.</Citation><ArticleIdList><ArticleId IdType="pubmed">30207670</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown R.H., Al-Chalabi A. Amyotrophic Lateral Sclerosis. N. Engl. J. Med. 2017;377:162&#x2013;172. doi: 10.1056/NEJMra1603471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J.J. Overview of Current and Emerging Therapies for Amyotrophic Lateral Sclerosis. Am. J. Manag. Care. 2020;26:S191&#x2013;S197. doi: 10.37765/ajmc.2020.88483.</Citation><ArticleIdList><ArticleId IdType="doi">10.37765/ajmc.2020.88483</ArticleId><ArticleId IdType="pubmed">32840332</ArticleId></ArticleIdList></Reference><Reference><Citation>McDermott C.J. Clinical trials in amyotrophic lateral sclerosis. Curr. Opin. Neurol. 2019;32:758&#x2013;763. doi: 10.1097/WCO.0000000000000731.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000731</ArticleId><ArticleId IdType="pubmed">31335338</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen S.P., Hall B., Castelli L.M., Francis L., Woof R., Siskos A., Kouloura E., Gray E., Thompson A.G., Talbot K., et al. Astrocyte adenosine deaminase loss increases motor neuron toxicity in amyotrophic lateral sclerosis. Brain. 2019;142:586&#x2013;605. doi: 10.1093/brain/awy353.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awy353</ArticleId><ArticleId IdType="pmc">PMC6391613</ArticleId><ArticleId IdType="pubmed">30698736</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson K., Chan J., Macklin E.A., Levine-Weinberg M., Breen C., Bakshi R., Grasso D.L., Wills A.-M., Jahandideh S., Taylor A.A., et al. Pilot trial of inosine to elevate urate levels in amyotrophic lateral sclerosis. Ann. Clin. Transl. Neurol. 2018;5:1522&#x2013;1533. doi: 10.1002/acn3.671.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.671</ArticleId><ArticleId IdType="pmc">PMC6292193</ArticleId><ArticleId IdType="pubmed">30564619</ArticleId></ArticleIdList></Reference><Reference><Citation>Filippi M., Bar-Or A., Piehl F., Preziosa P., Solari A., Vukusic S., Rocca M.A. Multiple sclerosis. Nat. Rev. Dis. Prim. 2018;4:43. doi: 10.1038/s41572-018-0041-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41572-018-0041-4</ArticleId><ArticleId IdType="pubmed">30410033</ArticleId></ArticleIdList></Reference><Reference><Citation>Walton C., King R., Rechtman L., Kaye W., Leray E., Marrie R.A., Robertson N., La Rocca N., Uitdehaag B., Van Der Mei I., et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult. Scler. J. 2020;26:1816&#x2013;1821. doi: 10.1177/1352458520970841.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458520970841</ArticleId><ArticleId IdType="pmc">PMC7720355</ArticleId><ArticleId IdType="pubmed">33174475</ArticleId></ArticleIdList></Reference><Reference><Citation>McGinley M.P., Goldschmidt C.H., Rae-Grant A.D., Author C. Diagnosis and Treatment of Multiple Sclerosis A Review Clinical Review &amp; Education JAMA|Review. Number. 2021;325:765. doi: 10.1001/jama.2020.26858.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.26858</ArticleId><ArticleId IdType="pubmed">33620411</ArticleId></ArticleIdList></Reference><Reference><Citation>Spitsin S., Koprowski H. Role of uric acid in multiple sclerosis. Curr. Top. Microbiol. Immunol. 2008;318:325&#x2013;342. doi: 10.1007/978-3-540-73677-6_13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-540-73677-6_13</ArticleId><ArticleId IdType="pubmed">18219824</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazzarino G., Amorini A.M., Petzold A., Gasperini C., Ruggieri S., Quartuccio M.E., Lazzarino G., Di Stasio E., Tavazzi B. Serum Compounds of Energy Metabolism Impairment Are Related to Disability, Disease Course and Neuroimaging in Multiple Sclerosis. Mol. Neurobiol. 2017;54:7520&#x2013;7533. doi: 10.1007/s12035-016-0257-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-016-0257-9</ArticleId><ArticleId IdType="pubmed">27826747</ArticleId></ArticleIdList></Reference><Reference><Citation>Toncev G., Milicic B., Toncev S., Samardzic G. Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur. J. Neurol. 2002;9:221&#x2013;226. doi: 10.1046/j.1468-1331.2002.00384.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1468-1331.2002.00384.x</ArticleId><ArticleId IdType="pubmed">11985629</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitmarsh T.E. The treatment of multiple sclerosis with inosine. J. Altern. Complement. Med. 2009;15:609. doi: 10.1089/acm.2009.0104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/acm.2009.0104</ArticleId><ArticleId IdType="pubmed">19500009</ArticleId></ArticleIdList></Reference><Reference><Citation>Spitsin S., Hooper D.C., Mikheeva T., Koprowski H. Uric acid levels in patients with multiple sclerosis: Analysis in mono- and dizygotic twins. Mult. Scler. 2001;7:165&#x2013;166. doi: 10.1177/135245850100700305.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/135245850100700305</ArticleId><ArticleId IdType="pubmed">11475439</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonsette R.E., Sindic C., D&#x2019;Hooghe M., De Deyn P.-P., Medaer R., Michotte A., Seeldrayers P., Guillaume D., ASIIMS Study Group Boosting endogenous neuroprotection in multiple sclerosis: The ASsociation of Inosine and Interferon beta in relapsing-remitting Multiple Sclerosis (ASIIMS) trial. Mult. Scler. 2010;16:455&#x2013;462. doi: 10.1177/1352458509360547.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458509360547</ArticleId><ArticleId IdType="pubmed">20200198</ArticleId></ArticleIdList></Reference><Reference><Citation>Junqueira S.C., dos Santos Coelho I., Lieberknecht V., Cunha M.P., Calixto J.B., Rodrigues A.L.S., Santos A.R.S., Dutra R.C. Inosine, an Endogenous Purine Nucleoside, Suppresses Immune Responses and Protects Mice from Experimental Autoimmune Encephalomyelitis: A Role for A2A Adenosine Receptor. Mol. Neurobiol. 2017;54:3271&#x2013;3285. doi: 10.1007/S12035-016-9893-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S12035-016-9893-3</ArticleId><ArticleId IdType="pubmed">27130268</ArticleId></ArticleIdList></Reference><Reference><Citation>Spitsin S., Hooper D.C., Leist T., Streletz L.J., Mikheeva T., Koprowski H. Inactivation of peroxynitrite in multiple sclerosis patients after oral administration of inosine may suggest possible approaches to therapy of the disease. Mult. Scler. 2001;7:313&#x2013;319. doi: 10.1177/135245850100700507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/135245850100700507</ArticleId><ArticleId IdType="pubmed">11724447</ArticleId></ArticleIdList></Reference><Reference><Citation>Toncev G. Therapeutic value of serum uric acid levels increasing in the treatment of multiple sclerosis. Vojnosanit. Pregl. 2006;63:879&#x2013;882. doi: 10.2298/VSP0610879T.</Citation><ArticleIdList><ArticleId IdType="doi">10.2298/VSP0610879T</ArticleId><ArticleId IdType="pubmed">17121380</ArticleId></ArticleIdList></Reference><Reference><Citation>Doyle C., Cristofaro V., Sullivan M.P., Adam R.M. Inosine&#x2014;A Multifunctional Treatment for Complications of Neurologic Injury. Cell. Physiol. Biochem. 2018;49:2293&#x2013;2303. doi: 10.1159/000493831.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000493831</ArticleId><ArticleId IdType="pmc">PMC7181455</ArticleId><ArticleId IdType="pubmed">30261493</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Shamarka M.E.S., El-Sahar A.E., Saad M.A., Assaf N., Sayed R.H. Inosine attenuates 3-nitropropionic acid-induced Huntington&#x2019;s disease-like symptoms in rats via the activation of the A2AR/BDNF/TrKB/ERK/CREB signaling pathway. Life Sci. 2022;300:120569. doi: 10.1016/j.lfs.2022.120569.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2022.120569</ArticleId><ArticleId IdType="pubmed">35472453</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J.J., Yoon J.H., Kim S.J., Yoo H.S., Chung S.J., Lee Y.H., Kang S.Y., Shin H.-W., Song S.K., Hong J.Y., et al. Inosine 5&#x2032;-Monophosphate to Raise Serum Uric Acid Level in Multiple System Atrophy (IMPROVE-MSA study) Clin. Pharmacol. Ther. 2021;109:1274&#x2013;1281. doi: 10.1002/CPT.2082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/CPT.2082</ArticleId><ArticleId IdType="pubmed">33064299</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>